ERBB2 and breast carcinoma: In summary, in this randomized phase II clinical trial of neoadjuvant chemotherapy ± bevacizumab in large or locally advanced HER2-negative primary breast cancer, high baseline MVD, reflecting the overall vascular density, was the only significant predictor of bevacizumab treatment response.